Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URO-902 in Overactive Bladder with Urge Urinary Incontinence
NCT04211831Phase 2Completed
- Sponsor
- Urovant Sciences
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 2 trial of hMaxi-K in overactive bladder (OAB), urge urinary incontinence (UUI), sponsored by Urovant Sciences. Started Dec 2019; status: completed.
02
Drugs
hMaxi-K
03
Conditions
overactive bladder (OAB)urge urinary incontinence (UUI)
Beyond the preview
Go deeper on NCT04211831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211831.